Subscribe
The FDA’s Pressure-Packed Alzheimer’s Drug Decision

Tradeoffs

The FDA’s Pressure-Packed Alzheimer’s Drug Decision

The U.S. Food and Drug Administration faces a costly and consequential decision over whether to approve a controversial new Alzheimer’s drug.
June 3, 2021

The FDA’s Pressure-Packed Alzheimer’s Drug Decision

The U.S. Food and Drug Administration faces a costly and consequential decision over whether to approve a controversial new Alzheimer’s drug.

Guest:

Caleb Alexander, Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health

View the transcript for today’s episode: https://tradeoffs.org/2021/06/03/the-fdas-pressure-packed-alzheimers-drug-decision

Take our short listener survey, and you could win a $50 gift card! bit.ly/TradeoffsSurvey

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter

Support this type of journalism today, with a gift: https://tradeoffs.org/donate

Follow us on Twitter: https://twitter.com/tradeoffspod

 


See acast.com/privacy for privacy and opt-out information.

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Proudly supported by:

cover
How Can Healthcare Workers Care for Themselves and Colleagues During Times of Grief Part 2 of 2: Practical Tools and Methods to Help Process Loss